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As glioma cells infiltrate the brain they become associated with various microanatomic brain structures such as blood
vessels, white matter tracts, and brain parenchyma. How these distinct invasion patterns coordinate tumor growth and
influence clinical outcomes remain poorly understood. We have investigated how perivascular growth affects glioma
growth patterning and response to antiangiogenic therapywithin the highly vascularized brain. Orthotopically implanted
rodent andhumanglioma cells are shown to commonly invade andproliferatewithin brain perivascular space. This form
of brain tumor growth and invasion is also shown to characterize de novo generated endogenousmouse brain tumors,
biopsies of primary human glioblastoma (GBM), and peripheral cancer metastasis to the human brain. Perivascularly
invading brain tumors become vascularized by normal brain microvessels as individual glioma cells use perivascular
space as a conduit for tumor invasion. Agent-based computational modeling recapitulated biological perivascular
glioma growth without the need for neoangiogenesis. We tested the requirement for neoangiogenesis in perivascular
gliomaby treating animalswith angiogenesis inhibitorsbevacizumab andDC101. These inhibitors induced theexpected
vessel normalization, yet failed to reduce tumor growth or improve survival of mice bearing orthotopic or endogenous
gliomas while exacerbating brain tumor invasion. Our results provide compelling experimental evidence in support of
the recently described failure of clinically used antiangiogenics to extend the overall survival of human GBM patients.
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544 A Mechanism of Glioma Formation Baker et al. Neoplasia Vol. 16, No. 7, 2014“Et pour arriver a une meilleure compréhension biologique des gliomes, l’analyse des
permiers débuts des processus gliomateux nous semble, pour le moment, plus
importante que celle des manifestations tardives.”“La croissance périvasculaire joue un
grand role, dans beaucoup de gliomes, comme phénomène de croissance primitive.”
“And to achieve a better biological understanding of gliomas, we believe that the
analysis of the earliest stages of glioma formation, for the moment, are more important
than the study of late manifestations.”“Perivascular growth plays an important role in
many gliomas as a phenomenon of early growth.”
[Hans Joachim Scherer, 1937]
Discovery is to see what everybody else has seen, and to think what nobody else
has thought.
[Albert Szent-Gyorgyi]
Introduction
Gliomas are brain cancers arising from transformed glial cells. Of all
gliomas, World Health Organization grade IV glioblastoma (GBM) is
the most prevalent and aggressive [1]. The diffusely invasive nature of
GBM precludes its complete surgical resection, which inevitably leads
to tumor recurrence and patient death within 15 to 21 months [2].
In the 1930s, Hans Joachim Scherer classified the pathology of
malignant glioma growth and invasion by examining several hundred
post-mortem brains of GBM patients. Scherer discovered that malignant
glioma cells are preferentially associated with four distinct microanatomic
structures: white matter fiber bundles, perineuronal spaces, the subpial
space, and brain microvessels [3,4]. Collectively, these infiltrative tumor
satellites have become known as the “secondary structures of Scherer”.
Despite his histopathologic observations, Scherer’s work was unable to
experimentally test the causes and biologic consequences of these various
forms of glioma growth and invasion. More recently, others have
demonstrated the occurrence of perivascular invasion in multiple
experimental brain tumor models [5–7], and it has been shown that
perivascular invasion increases in vascular endothelial growth factor
(VEGF)–deficient glioma cells [8,9] and brain tumor xenografts treated
with anti-VEGF blocking antibodies [10–13]. Clinical GBMs resistant to
bevacizumab therapy also demonstrate the tendency toward perivascular
invasion [14]. A better understanding of the cellular and molecular
mechanisms governing the behavior of glioma growth and invasion will
be required for the development of effective anti-GBM therapies.
How the behavior of individual glioma cells determines clinically
relevant macroscopic tumor growth remains poorly understood. We
demonstrate that orthotopic glioma cells (and glioma stem cells) frommice,
rats, and humans grow perivascularly throughout tumor progression
(i.e., from earliest stages to death of the host). We also observe perivascular
growth in human biopsies of primary GBM, genetically induced
endogenous mouse gliomas, and peripheral metastasis to the human
brain. Perivascular growth causes such tumors to become autovascularized
as they continuously grow along preexisting normal brain microvessels.
Agent-based computational modeling predicted that the perivascular
growth pattern was independent of neoangiogenesis. We tested this
prediction experimentally by blocking angiogenic signaling using
antibodies targeting the VEGF-A signaling axis. VEGF-A inhibitors
failed to curb progressive tumor growth and extend median survival in
multiple glioma models. Our data provide a novel interpretation and
understanding of perivascular brain tumor growth and invasion as a
VEGF-independent mechanism of tumor vascularization, which helps
explain why neoangiogenesis is dispensable for brain tumor progression
and why clinical antiangiogenics fail to meaningfully extend patient
survival in GBM. We propose that novel therapeutics ought tospecifically target normal brain blood vessels used by perivascularly
invading glioma cells to sustain progressive tumor growth.Materials and Methods
MalignantGliomaCell Lines and Patient-DerivedGBMSamples
The mouse GL26 glioma cell line was obtained from the
National Cancer Institute (Bethesda, MD). The rat CNS-1 glioma
cell line was kindly provided by William Hickey (Department of
Pathology, Dartmouth Medical Center, Lebanon, NH). HF2303
primary human GBM cancer stem cells were provided by Dr Tom
Mikkelsen, MD (Department of Neurology, Henry Ford Hospital,
Detroit, MI). The human U251 glioma cell line was provided by
the National Institutes of Health (Bethesda, MD) cell bank. The
human brain biopsy of mammary carcinoma metastasis was
provided by Dr. W.S. Nichols, and human GBM clinical biopsies
were obtained from neurosurgical patients at the University of
Michigan Health System after informed patient consent (Institu-
tional Review Board No. HUM00024610).Animal Strains
Six- to 7-week-old C57BL/6J, Rag1tm1Mom/J, and Rag1tm1MomTg
(TIE2GFP)287Sato/J mice were purchased from Jackson Laboratory
(Bar Harbor, ME). RA/EGxdelCre mice were kindly provided by
Angelika Bierhaus of the Department of Internal Medicine I, University
of Heidelberg (Heidelberg, Germany). LEW/SsNHsd Lewis rats (200-
240 g) were purchased commercially from Harlan Laboratories
(Indianapolis, IN). All animal experiments were conducted in accordance
with procedures approved by theUniversity Committee onUse andCare
of Animals and conformed to the policies and procedures of the Unit for
Laboratory Animal Medicine at the University of Michigan.Antibodies
The following primary antibodies were used: rat monoclonal anti-
CD31/Platelet Endothelial Cell Adhesion Molecule-1 (clone:
MEC13.3), Catalog No. 550274, BD Pharmingen (San Jose,
CA); rabbit polyclonal anti-laminin, Catalog No. L9393, Sigma-
Aldrich (St. Louis, MO); mouse monoclonal anti-human nestin
(clone: 10C2), Catalog No. MAB5326, Millipore (Billerica, MA);
mouse monoclonal anti–α-smooth muscle actin (SMA; clone: 1A4),
Catalog No. M0851, Dako (Carpenteria, CA); humanized mouse
monoclonal anti–VEGF-A (bevacizumab, Avastin), NDC: 50242-
060-01, Genentech (San Francisco, CA); non-specific IgGs,
Equitech-Bio Inc. (Kerrville, Tx).Generation of De NovoMouse GBM Using the Sleeping Beauty
Transposase System
De novo GBMs were induced in mice using the Sleeping Beauty
transposase system as previously described [15]. Plasmids encoding p53
shRNA and oncogenic NRAS, each flanked by Inverted Repeat/Direct
Repeat sequences, were co-injected into the lateral ventricle of neonatal
C57BL/6J mice along with a plasmid encoding the Sleeping Beauty
transposase at a ratio of (1:1:1). Tumor formation was monitored by
bioluminescence imaging due to luciferase expression by the Sleeping
Beauty plasmid. Mice developing signs of tumor burden were
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tochemical evaluation.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA). Data are reported as mean ±
SEM and were examined with the statistical tests specified in each figure
legend. Values were considered significant at the P ≤ .05 level.
Results
Orthotopic Glioma Growth Is Patterned by Preexisting
Brain Microvasculature
Since human malignant glioma is known to associate with distinct
microanatomic brain structures, we initially sought to characterize the
routes ofmigration used by experimental GBMcell lines from the earliest
time points following their intracranial implantation until moribundity.
To facilitate tumor cell visualization at single cell resolution, we
genetically modified mouse (GL26) and rat (CNS-1) glioma cell lines to
express mCitrine fluorescent protein, a bright and photostable mutant of
yellow fluorescent protein [16]. The resultant fluorescently modified cell
lines were referred to as GL26-Cit and CNS-1-Cit, respectively.
Detailed time-course analyses of intracranial GL26-Cit glioma growth
from 15 minutes to 120 hours post-implantation (hpi) into the right
striatum of 6- to 7-week-old syngeneic RAG1−/− mice revealed three
distinct phases of early glioma growth over nine time points analyzed
(n = 54; six mice per time point) (Figure 1, A and B). Tumors b24 hpi
were characterized by round glioma cells confined to the site of initial
tumor implantation (phase I). Tumor morphology then shifted after
24 hours displaying chains of elongated glioma cells radiating away from
the site of initial tumor implantation that assumed a branch-like structure
(phase II). Tumor centers became increasingly dense with glioma cells
N96 hours in vivo, resulting in a progressive widening of the tumor mass
while maintaining an invasive pattern at its margins (phase III).
The growth pattern of phase II (invasive) gliomas was reminiscent
of branching (i.e., bifurcating) blood vessel architecture. To test
whether GL26-Cit glioma uses preexisting brain microvasculature as a
microanatomic scaffold for tissue invasion, we performed fractal
dimension analysis on fluorescence scanning confocal micrographs of
these tumors using the box-counting algorithm of ImageJ quantitative
analytical software (National Institutes of Health). This allowed us to
obtain a quantitative description of tumor morphology. Tumor
fractal dimension values (D values) were compared to those obtained
from tumor-naïve microvasculature of two distinct transgenic mouse
strains (RA/EGxdelCre and Rag1tm1MomTg(TIE2GFP)287Sato/J),
both of which express green fluorescent protein (GFP) in brain
endothelium [17,18] (Figure 1C). Our analysis indicated that invasive
gliomas (48 hpi) displayed an average D value of 1.532 ± 0.015,
directly overlapping the average D value obtained from tumor-naïve
mouse brain microvasculature (1.567 ± 0.024). However, preinva-
sive gliomas (0.25 hpi) had significantly lower average D values
(1.230 ± 0.010) (Figure 1D). The overlap in the fractal dimension of
invasive gliomas with that of tumor-naïve brain microvessels indicated
that GL26-Cit assumes microvasculature-like morphology at the
onset of tumor invasion. This implicated the use of preexisting brain
microvessels as a scaffold for GL26-Cit glioma invasion as previously
observed in mouse GL261 and rat C6 gliomas [5–7].
To substantiate our hypothesis, we implanted GL26-Cit glioma
cells directly into the brain of RA/EGxdelCre mice. Fluorescencescanning confocal microscopy was used to analyze tumor morphology
in brain tissue sections corresponding to the aforementioned nine
time points (n = 54; six mice per time point). Not only did we find
direct evidence for GL26-Cit cells using preexisting mouse brain
microvessels as a scaffold for tumor invasion (Figure 1E), but we were
also unable to find even a single example of these cells using any other
known route of glioma invasion throughout the 324 brain tissue
sections analyzed among 54 mice. Transcardial injections of
fluorophore-conjugated lysine-fixable dextrans and immunohisto-
chemistry with blood vessel–specific antibodies (i.e., CD31, α-SMA,
and laminin) were used as alternative methods to label mouse brain
microvessels (Figure S1). Both methods corroborated the presence of
microvasculature-associated growth and invasion. We conclude that a
strict association with preexisting brain microvasculature characterizes
the intracranial invasion of GL26-Cit glioma.
To further examine GL26-Cit perivascular invasion, we performed
intravital imaging with multiphoton laser scanning microscopy to
examine brain tumor growth and invasion in real time through cranial
windows installed over the somatosensory cortex of living RAG1−/−
mice. Phase II brain tumors (i.e., 48 hpi) were imaged for up to 24 hours
in mice maintained under anesthesia with inhaled isoflurane (n = 10).
Mouse brain microvessels were visualized by intravenous tail-vein
injections of rhodamine B isothiocyanate–conjugated dextrans (mw =
70 kDa) before fitting the animal on the microscope stage. Imaging
experiments revealed the dynamics of early microvasculature-associated
GL26-Cit invasion in real time at single-cell resolution, further
demonstrating that GL26-Cit glioma invasion is guided by preexisting
brain microvasculature (Figure 1F and Movie S1).
We next asked whether perivascular invasion occurs throughout the
entire course of brain tumor progression. To assess this, we implanted low
numbers of GL26-Cit cells (from 300 to as few as 10) into the striatum of
RAG1−/− mice. Implantations of approximately 10 GL26-Cit cells
extendedmedian survival to nearly 60 days from amedian survival of only
21 days at a dose of 300 cells (Figure 1G). Histologic analysis of GL26-
Cit glioma during end-stage disease [i.e., 58 days post-implantation (dpi)]
confirmed the presence of continuous perivascular invasion (Figure 1G).
Identification of the Microanatomic Niche Occupied by
Perivascularly Invading Glioma Cells
To determine the microanatomic localization of perivascular
glioma cells, we labeled GL26-Cit cells in vitro with electron-dense
ultrasmall particles of iron oxide (USPIOs) and visualized these cells
using transmission electron microscopy (TEM). TEM samples
bearing gliomas corresponding to phase II (invasive) tumor growth
(n = 6) were chosen to capture perivascular migration. TEM analysis
consistently revealed invasive glioma cells in juxtaposition to the
vascular basement membrane that covers the abluminal surface of
brain microvessels (Figures 1H and S2). GL26-Cit tumor cells
displaced normal brain tissue adjacent to the adluminal microvessel
surface as they entered and migrated throughout the perivascular
space, a potential space facilitating bulk diffusion of interstitial fluid
throughout the brain [19–21]. The process of iterative perivascular
glioma growth and invasion is illustrated in Figure 2 (A and B).
Brain Tumors of Diverse Species and Cellular Origin Exhibit
Perivascular Invasion
We next evaluated whether perivascular invasion characterized
brain tumors of species other than mouse. Indeed, both rat CNS-1-
Cit glioma cells implanted into the striatum of syngeneic Lewis rats
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Figure 1. GL26-Cit glioma uses preexisting brain microvasculature as a scaffold for brain tumor invasion. (A) Tumor growth timeline
indicating the time points analyzed over the first 120 hours of intracranial GL26-Cit glioma growth. Colored bars represent time frames
corresponding to the three distinct phases of early intracranial GL26-Cit glioma growth. (B) Representative fluorescence scanning confocal
micrographs of GL26-Cit glioma in the RAG1−/− mouse striatum imaged at the nine predetermined time points indicated in A.
(C) Representative fluorescence scanning confocalmicrographs ofmouse brainmicrovessels fromRA/EGxdelCre (left) andRag1tm1MomTg
(TIE2GFP)287Sato/J (i.e., Tie-2-GFP) (right) mice used to determine the fractal dimension of normal mouse brain microvasculature. Fractal
dimension values (D values) for eachmicrograph are shown. (D) AverageD values of gliomas fromRAG1−/−mice at 0.25 and 48 hpi (n = 6
mice per group) compared to the averageD value of brainmicrovasculature from the twoGFP+mouse strains represented in C (n = 8; four
mice per strain with five distinct striatal regions imaged per mouse). ***P b .0001 versus tumors 0.25 hpi; one-way analysis of variance
followed by Tukey post-test. Data represent the mean ± SEM. (E) Fluorescence scanning confocal micrograph of GL26-Cit glioma 48 hpi
into the RA/EGxdelCremouse striatum. GFP+mouse brainmicrovessels have been pseudocolored red.White arrowheads point to several
examples of microvasculature-associated glioma invasion. (F) Intravital multiphoton micrograph of GL26-Cit glioma imaged through an
intracranial window 120 hpi into the somatosensory cortex of the RAG1−/− mouse brain (imaging depth = 129 μm). Mouse brain
microvasculature was labeled intraluminally by tail-vein injection of rhodamine B isothiocyanate–conjugated dextran (mw = 70 kDa)
before imaging.White arrowheads point to numerous examples ofmicrovasculature-associated tumor invasion. (G) GL26-Cit after 58 days
post-tumor implantation into the RAG1−/− mouse brain shown at low (left) and high (right) magnification. Kaplan-Meier survival analysis
(lower right) demonstrates that initial injections of low numbers of glioma cells extend animal survival to study late-stage tumor invasion.
(H) TEMat lowpower (top image) showing longitudinal and transverse capillary segments (pseudocolored red) enveloped by perivascularly
invading GL26-Cit glioma cells (cytoplasm, green; nuclei, blue) 48 hpi in the RAG1−/−mouse brain. Tumor cells displace the immediately
surrounding neuropil as they enter the perivascular space. White arrows indicate USPIOs used to label tumor cells in vitro before
implantation. Higher magnification image of the area outlined by the white box is shown below. Black arrowheads in lower micrograph
point to the vascular basement membrane covering the adluminal surface of the vascular endothelium. L, vessel lumen.
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implanted into the striatum of NU/J (i.e., nude) mice [22] (n = 5)
used brain microvasculature as a scaffold for tumor invasion
(Figure 3, A and B).
Transformed glial cells with stem cell-like properties are thought
to be important contributors to clinical brain tumor initiation and
progression [23]. We therefore wished to see if perivascular invasion
characterized the behavior of bona fide GBM cancer stem cells. To
test this, we used a patient-derived sample of primary human GBM
cancer stem cells, referred to as HF2303 [24]. These cells form
neurospheres when grown under serum-free conditions in the
presence of human epidermal growth factor and human basic
fibroblast growth factor. HF2303 cells have previously been shown
to 1) express the neural stem cell markers Sox2, Musashi-1, and
nestin; 2) phenocopy the original patient-derived tumor when
orthotopically xenografted into immunocompromised rodents;
3) differentiate into both glial and mesenchymal cell lineages
when grown intracranially [24]. HF2303 cells implanted into the
striatum of RAG1−/− mice (n = 15) overtly demonstrated perivas-
cular-associated invasion that persisted to the moribund state ~143 dpi
(Figure 3C). This result indicated that perivascular invasion may
underlie the invasion of clinical GBM cancer stem–like cells. We
conclude that perivascular invasion is a common mechanism of
orthotopic GBM invasion.
Brain microvasculature has been proposed as the “soil” in Paget’s
“seed and soil” hypothesis of metastasis formation [25,26]. We
therefore wished to determine whether perivascular invasion also
characterizes peripheral metastasis to the brain. Histologic examina-
tion of hematoxylin and eosin–stained tissue biopsies from a human
patient with mammary carcinoma metastasis to the brain revealed
extensive perivascular invasion at the infiltrative tumor margin
(Figure 3D). This finding corroborates the notion of brain
microvasculature as “soil” in brain metastasis and demonstrates that
even peripheral cancers preferentially use preexisting microvessels as a
scaffold for tissue invasion upon entering the brain.De Novo Endogenous Mouse GBM and Clinical GBM Biopsies
Exhibit Perivascular Invasion
We next wished to test whether perivascular invasion also occurs in
endogenous brain tumors. To test this, we generated de novo mouse
GBMs by co-injecting plasmids encoding p53 shRNA and oncogenic
NRAS, each flanked by IR/DR sequences, along with a plasmid
encoding the Sleeping Beauty transposase at a ratio of 1:1:1 into the
lateral ventricle of neonatal C57BL/6J mice. Resultant GBMs were
positive for the neural precursor marker, nestin, which was used to
identify tumor cells. Co-immunolabeling with anti-nestin and anti–
Von Willebrand factor antibodies was used to test the association of
endogenous GBM cells with brain microvessels. Invasive nestin+
tumor cells at the infiltrative tumor margins were extensively
associated with preexisting microvasculature (Figure 4A). We
conclude that perivascular invasion characterizes the invasion of
tumor cells arising de novo from brain-resident cells and also rules out
the notion that perivascular invasion is an artifact of orthotopic brain
tumor implantation.
The clinical relevance of perivascular invasion rests upon whether
this phenomenon also occurs in human GBM. We therefore wished
to test whether human GBM clinical biopsies would also reveal
evidence of perivascular invasion. Human GBM patient biopsies were
examined by a clinical neuropathologist blinded to the location of
each sample. Biopsies determined to contain both glioma and normal
tissue were assumed to represent the zone of transition between these
two tissue types (i.e., the infiltrative tumor margin). These biopsies
were then chosen for immunohistochemical analysis in our
laboratory. Biopsy tissue contained cells immunoreactive for
Vimentin (a marker of brain progenitor cells) and Von Willebrand
factor (a marker of blood vessels). Co-immunolabeling with these two
antibodies revealed the presence of perivascular-associated Vimentin+
tumor cells at the transition zone between neoplastic and normal
tissues (Figure 4B). This important finding substantiates perivascular
tissue invasion as a clinically relevant mechanism of human malignant
brain tumor growth.
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Figure 2. Perivascular invasion is an iterative growth process. (A) Scanning fluorescence confocalmicrographs of GL26-Cit glioma cells from
0.25 to 120 hours in the RA/EGxdelCre mouse brain. Glioma cells are shown in green; brain microvessels are shown in red. (B) Schematic
representation of the process of perivascular glioma growth and invasion beginning immediately post-tumor implantation (Step 1-2).
Implanted glioma cells initially infiltrate throughout the perivascular space (Step 3-4). Cell division causes normal brain parenchyma present
between adjacent microvessels to be displaced by neoplastic tissue, leaving normal brain microvessels within the tumor core (Step 4-5).
Iterations of further perivascular invasion and cell division produce well-vascularized brain tumors throughout tumor growth (Steps 6-8).
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We constructed an agent-based computational model to identify
the minimum number of biologic parameters required for the
emergence of a perivascular pattern of brain tumor invasion. An
agent-based model was chosen for its ability to simultaneously
simulate the operations and interactions of multiple agents (i.e.,
individual glioma cells) with the underlying assumption that simple
behavioral rules can generate complex behavioral patterns, leading
to emergent phenomena [27]. For our purposes, we were interested in
applying an agent-basedmodel to simulate intracranial glioma behavior at
the single-cell level under the assumption that glioma cells exhibit a
predilection for preexisting brain microvasculature, as demonstrated by
our empirical observations.
The model describes individual glioma cells by a position x!ið Þ, a
velocity v!ið Þ, and an orientation vector ω!ið Þ, whose angle is denoted
by θi [i.e., ω!i ¼ coshi; sinhið Þ] on a two-dimensional blood vessel
domain taken from real mouse brain microvessel data, which is described
by a density distribution g that remains static over time (i.e., blood vessel
density and position do not change over the course of the simulation).
Wemodel the displacement of each cell by a correlated randomwalk [28],
where the transition probabilities for a single cell only depend on its last
position and direction of motion. However, the displacement of glioma
cells is influenced by the presence of nearby blood vessels. The motion
of an individual glioma cell is fully described by the following
differential equation:
d x!i
dt
¼ C x!ið Þ ω!ið Þ; dhi ¼ vPω!iT ∇g x!ið Þð Þdt þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2r dBt
p
ð1Þ
where the migration speed of the each glioma cell C x!ið Þ is a constant
(i.e., v!ij j ¼ C) and is only dependent on the glioma cell’s association
with a blood vessel (BV) according to the following rule:
C x!ið Þ ¼ C0 if g x
!
ið Þ N 0 x!i on a BVð Þ
C1 if g x!ið Þ¼ 0 x!i not on a BVð Þ

ð2Þ
Glioma cells contacting a blood vessel move slower due to adhesion
effects, thus we takeC1 N C0. The predilection of glioma cells for blood
vessels is expressed by the velocity field vPω!iT ∇g x!ið Þð Þ, where the
gradient ∇g x!ið Þð Þ indicates the direction of largest increase of blood
vessels. This velocity field attracts the glioma cells toward nearby blood
vessels. We further denote the projection operator Pω!i T by:
Pω!iT F
!  ¼ ω!iT•F!¼ − sinhcosh
 
•F
! ð3Þ
This projection ensures that the blood vessel attractive force only
changes the direction, not the speed, of the glioma cell’s migration.
Finally, the term dBt signifies the stochastic noise in the system by
modeling the random perturbations exerted on glioma cells. The
parameter σ in Equation (1) controls the intensity of this
perturbation. Upon contacting a blood vessel (i.e., g x!ið ÞN0 ),
glioma cells divide at a rate μb and reduce their migration speed due
to adhesion effects. The daughter cell created upon cell division
then begins its own independent correlated random walk. Glioma
cells not in contact with a blood vessel (i.e., g x!ið Þ ¼ 0) eventuallydie at a rate μd, where the life expectancy of an individual glioma cell
is defined as 1/μd. The key elements of the model, and its
comparison to in vivo glioma growth, are summarized in Figure 5 (A
and B). To implement the model numerically, we discretize the
equation using the Euler method [29]. By optimizing only few
parameters such as cell migration speed, strength of attraction to
blood vessels, and cell birth and death rate, we have non-trivially
recapitulated the three distinct phases of early malignant glioma
growth shown empirically through our experimental data
(Figure 5C and Movie S2). Further details on the agent-based
computational model can be found in the Supplementary Materials
and Methods section (Figures S3 and S4).
Perivascular Glioma Invasion Is a VEGF-Independent
Mechanism of Tumor Vascularization
The growth pattern obtained from our in silico simulation using
preexisting mouse brain microvasculature as a domain in which simulated
glioma cells interact and evolve over time bore a striking resemblance to
experimental data. Since our in silico simulation did not implement a
parameter controlling tumor neoangiogenesis (i.e., the blood vessel domain
remains static over the course of the simulation), the model predicted that
perivascular invasion is independent of neoangiogenesis to sustain
progressive tumor growth. We began to test this prediction by treating
RAG1−/−mice bearingGL26-Cit tumors over a 144-hour time period (n =
30; two groups; five time points; three mice per group per time point) with
bevacizumab, a neutralizingmonoclonal antibody against VEGF-A [30], at
a dose of 10 mg/kg delivered intraperitoneally (i.p.) twice weekly as
previously described [31] or with non-specific control IgGs at an equivalent
molar dose, route, and schedule serving as a negative control. Tumors
corresponding to 24, 48, 96, 120, and 144 hours post-tumor implantation
revealed no significant differences in overall tumor size or morphology
between treatment groups at matched time points (Figure 6, A–C).
Bevacizumab’s presence in the brain was confirmed by probing mouse
brain tissue sections with secondary antibodies against the humanized Fc
region of bevacizumab (Figure S5). This analysis revealed large amounts of
bevacizumab antibody throughout the entirety of the brain tumor and at
remote distances throughout the surroundingnormal brain tissue. Evidence
of bevacizumab’s biologic efficacy in stabilizing tumor-associated blood
vessels (i.e., vessel normalization) was demonstrated by using antibodies
against the vascular marker CD31. Tumor blood vessel integrity was
preserved in bevacizumab-treatedmice while being disrupted in the tumors
of mice treated with control IgG antibodies (Figure 6D). These results
confirmed the vasculature “normalizing” effect of bevacizumab, in which
VEGF inhibitors stabilize normal vascular architecture, thus increasing
vascular perfusion and reducing vasogenic edema [32–34].
We next tested the effect of bevacizumab on the survival of mice
bearing perivascularly invading gliomas. Kaplan-Meier survival
analysis was performed on RAG1−/− mice treated with either
bevacizumab or control IgG. Bevacizumab treatment failed to
significantly extend the overall survival of mice bearing orthotopically
implanted GL26-Cit mouse glioma (Figure 6E) or mice bearing
oncogene-induced endogenous mouse brain tumors (Figure 6F).
We also used DC101, a monoclonal blocking antibody targeting
the mouse Vascular Endothelial Growth Factor Receptor-2 (VEGFR-
2) (flk-1/kdr) [35] as an alternative VEGF inhibitor at a dose of 40
mg/kg delivered i.p. twice weekly as previously described [36,37] and
compared its effect to control IgG (n = 30; five time points; three
mice per group per time point). Treatment with DC101 also revealed
no significant differences in overall GL26-Cit tumor size or
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Figure 3. Brain tumors of diverse species and cellular origin exhibit perivascular invasion. (A) Fluorescence scanning confocal
micrographs of fluorescently modified CNS-1-Cit rat glioma cells in the brain of syngeneic Lewis rats after 48 hpi (left image) and 72 hpi
(right two images). Brain microvasculature was immunolabeled with anti-laminin antibodies, a marker of the vascular basement
membrane. White arrowheads point to distinct examples of microvasculature-associated tumor invasion. (B) Nissl staining of human
U251 glioma cells in NU/J mice 72 hpi. Black boxes in each brightfield micrograph outline the field of view shown to the right at increasing
magnification. Black arrows in the far right image point to tumor cell bodies heavily stained with Nissl that assume vascular morphology
as they migrate away from the main tumor mass. N, tumor necrosis. (C) Fluorescence scanning confocal micrographs of HF2303 primary
human GBM cancer stem cells 14 and 143 dpi into the RAG1−/− mouse striatum. Primary human GBM cancer stem cells are
immunoreactive for the neural stem cell marker nestin. Brain microvessels have been labeled with anti-CD31 antibodies. White
arrowheads indicate several examples of microvasculature-associated tumor invasion. T, bulk tumor mass. (D) Tissue biopsy from a
human patient bearing mammary carcinoma metastasis to the brain. The metastatic lesion (purple) seen at low magnification (top left
panel) can be seen adjacent to a large superficial blood vessel heavily infiltrated with perivascular tumor cells (white arrowheads). Higher
magnification (bottom left panel) of the area outlined by the black box in the panel above reveals the invasive margin of the metastatic
lesion. Largest panel to the right shows the invasive margin outlined by the black box in the bottom left image at ×20 magnification.
White arrowheads point to several examples of invasive cancer cells (purple) surrounding brain microvessels (seen in red due to the
presence of intraluminal red blood cells).
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points over the 144-hour analysis period (Figure 7A). Kaplan-Meier
survival analysis performed on RAG1−/− mice treated with either
DC101 or control IgG (n = 10; 5 mice per treatment group)
confirmed the failure of anti-VEGF therapy to significantly improve
the overall survival of mice bearing perivascularly invading glioma
(Figure 7B). Further experiments using DC101 as an adjuvant
therapy in combination with an efficacious anti-glioma gene
therapeutic strategy [38,39] against GL26-bearing C57BL/6J mice
revealed that DC101 also fails to provide additional survival benefit
compared to gene therapy plus control IgG, or saline treatment alone,
either before, or after, the administration of gene therapy (n = 30; 5
mice per treatment group) (Figure 7, C and D).
Conflicting evidence over whether bevacizumab can block the
activity of murine VEGF-A [40–43] prompted us to treat RAG1−/−
mice bearing primary human HF2303 GBM stem cells with the drug
at the aforementioned dose, route, and schedule. Even after 54 total
doses, given over 162 days of tumor growth, bevacizumab failed to
significantly extend overall survival compared to treatment with
control IgGs (Figure 8A). The brains of moribund mice were
removed and photographed to document gross brain morphology
before sectioning. While the brains of non-specific IgG-treated
control mice exhibited extensive microvascular hemorrhage, evidence
of microvascular hemorrhage was completely absent in mouse brains
treated with bevacizumab (Figure 8B). Immunohistochemistry with
human-specific anti-nestin and anti-CD31 antibodies revealed
normalized tumor microvasculature deep within tumor tissue in
bevacizumab-treated mice, as seen previously in bevacizumab-treated
mouse GL26-Cit tumors. Conversely, control IgG–treated brain
tumors revealed fragmented microvessels lacking mature microvascular
architecture (Figure 8C). Treatment with bevacizumab also exacerbated
tissue invasion (Figures 8C and S6). Control IgG–treated tumors grew
in a nodular fashion and appeared to compress the contralateral
hemisphere, while bevacizumab-treated brain tumors exhibited a more
diffuse growth pattern, crossing over into the contralateral striatum
without evidence of compression. These results are compatible with the
beneficial effects of bevacizumab in humanGBMpatients (i.e., reduced
intracerebral edema and improved brain function).
The phenomenon of perivascular glioma invasion, coupled with
ultrastructural data indicating that glioma cells displaced normal brain
tissue as they enter brain perivascular space, prompted us to quantifythe average intervessel distance in the brain and the average size of
glioma cells in situ so that we could estimate the number of glioma
cells required to occupy the space between neighboring microvessels.
To do so, we measured average intervessel distance in the striatum
using confocal micrographs of brain tissue sections from immuno-
labeled C57BL/6J or GFP+ endothelium from RA/EGxdelCre mice
using Leica analytical software (Figure 9, A and B), which both reveal
calculated average intervessel distances (AIVDcalc) of 56 μm in two
dimensions. Micrographs of perivascularly invading GL26-Cit glioma
cells over the first 120 hours in vivo were used to calculate an average
tumor cell diameter (ACDcalc) of 21 μm (Figure 9C), indicating that as
few as three glioma cells (or 56 μm/21 μm) are required to span the
distance between adjacentmicrovessels. Furthermore, a sphere ofmouse
brain tissue 1mm3 is densely filled with brainmicrovessels (Figure 9D),
thus perivascular invasion and high brainmicrovascular network density
promote well-vascularized tumors early in development. On the basis of
these quantitative results of brain microvessel density and the insights
gained from our experimental and computational modeling of
perivascular brain tumor growth, we propose a model of iterative,
neoangiogenesis-independent, perivascular brain tumor growth and
invasion referred to as “autovascularization” (Figure 10).Discussion
Our investigations have elucidated how the preference of rodent
malignant glioma cells and human glioma stem cells to migrate within
brain perivascular space allows glioma cells to achieve diffuse brain
infiltration and the formation of lethal macroscopic tumors without
the need for new blood vessel formation. However, earlier literature
has proposed that nascent tumors form without direct access to blood
vessels and only grow to a limited volume (1 mm3 or 1 × 106 cells)
before necessitating access to VEGF-dependent neovascularization to
rescue tumors from dormancy [5,7,44,45]. Our work shows that
avascular tumor growth is impossible in the context of the brain, as a
sphere of brain tissue 1 mm3 is already densely filled with brain
microvessels. This quantitative analysis also suggests that only three to
six glioma cells will suffice to fill the space between two adjacent
microvessels by displacing normal brain parenchyma as they invade
and divide within the perivascular space. It is therefore apparent that at
no time during malignant brain tumor progression is the tumor mass
devoid of a blood supply, effectively precluding an avascular phase of
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Figure 4. De novo mouse GBM and clinical GBM biopsies exhibit perivascular invasion. (A) De novo mouse GBM generated using the
Sleeping Beauty transposase system at 60 days post-plasmid injection. At the center, a 5× mosaic epifluorescence micrograph of a
coronal mouse brain tissue section is shown. Tumor cells have been labeled using anti-nestin antibodies. Brain microvasculature has
been labeled with anti–Von Willebrand factor antibodies. 4',-diamidino-2-phenylindole (DAPI) has been used as a counterstain (blue).
Numbered white boxes within the central epifluorescence micrograph correspond to respectively numbered higher magnification
fluorescence scanning confocal micrographs surrounding it. Several examples of perivascular tissue invasion are indicated by white
arrowheads. (B) Human GBM clinical biopsy. A 5× mosaic epifluorescence micrograph of a tissue biopsy immunolabeled with anti-
vimentin antibodies, anti–Von Willebrand factor antibodies, and DAPI (blue) as a counterstain is shown. The zone of transition between
tumor tissue (left) and normal brain (right) lies within the white dashed lines overlying each fluorescence channel. Panels below the high-
magnification fluorescence scanning confocal micrographs correspond to the dashed white boxes from the epifluorescence images
above. White arrowheads in each confocal micrograph point to examples of perivascular tissue invasion.
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comparable to the surrounding normal brain [46] supporting the
notion that human glioma progression may proceed by
autovascularization.
Perivascular invasion causes spontaneous tumor vascularization in a
VEGF-independent manner by engulfing preexisting brain micro-
vessels and replacing normal brain parenchyma over the course of
tumor progression (see Figure 10). We propose the term “auto-
vascularization” to describe this form of continuous brain tumor
growth and invasion. The VEGF independence of glioma auto-
vascularization is supported by our data showing that the use of
VEGF inhibitors bevacizumab and DC101 fail to curb tumor
progression or improve median survival in mice bearing human or
mouse malignant glioma.
The brain perivascular compartment is a potential space between
the vascular basement membrane and the immediately surrounding
glia limitans, derived from [19] astrocytes which impart blood–brain
barrier characteristics to the vascular endothelium. Because brain
perivascular space serves as the point of entry for oxygen, glucose, and
other nutrients into the brain, it is ideally suited to support the high
metabolic demand of rapidly proliferating tumor cells. Perivascular
tumor cells therefore benefit from the ample amounts of glucose
entering the brain for use in the glycolytic pathway, the preferred
metabolic pathway of transformed cells according to the Warburg
effect [47]. Indeed, it has recently been shown that anaerobic
glycolysis is favored by brain tumor initiating cells, cells thought
responsible for initiating and maintaining progressive tumor growth
in human glioma [48]. The basement membrane covering the
adluminal microvessel surface is rich in extracellular matrix proteins
such as laminin, fibronectin, and vitronectin. These highly
glycosylated extracellular matrix proteins are binding partners in
integrin-mediated cellular adhesion, promote cellular migration, and
activate pro-survival signaling pathways [49]. For these reasons, the
preference of invasive glioma cells for brain perivascular space may
serve to 1) provide an oxygen, glucose, and nutrient-rich microen-
vironment ideal for the survival of highly metabolic neoplastic tissue
and 2) promote cell adhesion/migration and stimulate pro-survival
pathways in cancer cells.
Though the literature regarding the inhibitory effect of bevacizu-
mab against mouse VEGF-A (mVEGF-A) is contradictory, the
original developers of A.4.6.1, a mouse anti-VEGF monoclonal
antibody subsequently humanized and branded as bevacizumab
(Avastin) [50], maintain that the antibody has low affinity for
mVEGF-A. However, various research groups have shown the
biologic efficacy of bevacizumab against mVEGF-A [41–43], and
our own results showing brain tumor vessel normalization are allconsistent with the claim that bevacizumab indeed blocks mVEGF-A.
A dose of 10 mg/kg delivered i.p. every 3 days normalized tumor-
associated mouse brain microvessel architecture in the murine GL26-
Cit glioma model. This effect was comparable to that demonstrated
by bevacizumab treatment of HF2303 cells, primary human GBM
cancer stem cells, suggesting that bevacizumab in fact exerts a biologic
effect on both human- and mouse-derived VEGF-A in vivo.
Blood–brain barrier compromise leads to intracerebral vasogenic
edema and neurologic symptoms in GBM [51]. VEGF inhibitors,
such as bevacizumab, are therefore thought to improve quality of life
by stabilizing normal brain microvessel structure and reducing brain
edema [32,33]. Our experimental data with HF2303 human glioma-
derived stem cells treated with bevacizumab demonstrate the
normalizing effect on tumor-associated microvasculature in a model
of primary human GBM stem cells; these experiments also
demonstrate the substantial increase in the invasion of human glioma
stem cells caused by bevacizumab [11,52]. We therefore conclude
that bevacizumab-mediated symptom reduction likely involves 1) a
reduction in intracerebral vasogenic edema by stabilizing tumor-
associated brain microvessels and 2) a lessening of intracerebral
compression of eloquent brain regions by exacerbating diffuse tumor
invasion. This suggests that VEGF inhibitors, despite potential
beneficial effects, may be deleterious to patients by promoting
widespread tumor invasion. The recently reported failure of
bevacizumab to prolong patient life in randomized human glioma
clinical trials [53,54] is compatible with our results. Indeed, our data
provide a basic biological framework potentially underlying these
clinical results. It remains to be examined whether increased invasion
caused by bevacizumab is dependent on basal levels of tumor-derived
VEGF secretion or the intrinsic tendency for glioma cells to invade
perivascularly [12,55,56].
We have not overlooked the fact that malignant glioma cells may
use other growth pathways in addition to, or in lieu of, the
perivascular space. However, we suspect that all forms of malignant
glioma invasion may preclude the requirement for new blood vessel
formation to support tumor progression. In the future, we aim to
further examine and catalogue the diverse invasion patterns of
malignant glioma cells. By identifying the various ways in which
malignant glioma cells invade the brain, combinatorial therapeutics
that block multiple migration pathways in order to effectively treat
human malignant brain tumors may be developed. We propose that
new therapies directly targeting the perivascular space and normal
brain blood vessels that sustain glioma growth and invasion may
prove efficacious targets in the treatment of malignant glioma by
curbing diffuse tumor infiltration throughout the interconnected
microvessel network. Cytotoxic therapies targeting tumor-associated
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Figure 5. In silico computational modeling mimics perivascular brain tumor growth. (A) Schematic representation of an agent-based
computational model describing perivascular brain tumor growth and invasion. Individual glioma cells move toward nearby blood vessels
under the influence of a velocity field vPω!iT ∇g x!ið Þð Þ thatmimics the predilection of glioma cells for blood vessels (an underlying assumption
of themodel). Cellsmoveby a correlated randomwalkwith constant speed towardnearbyblood vessels.Once tumor cellsmake contactwith
a vessel, they slow their migration speed and proliferate at a rate μb. Tumor cells not associated with a blood vessel eventually undergo cell
death at a rate μd and have an average life expectancy of 1/μd. BV, blood vessel. (B) A table summarizing the parameters used in the agent-
basedmodel. The respective symbols and optimal values are indicated for each parameter. (C) Representative snapshots of simulated brain
tumors corresponding to the three phases of early perivascular tumor growth. The microvasculature domain (vessels only) has been taken
from a fluorescence scanning confocalmicrograph of RA/EGxdelCremouse brainmicrovessels. The simulated tumor initially consists of 1×
103 cells centeredwith themicrovasculature domain at t = 0, simulating preinvasive phase I glioma soon after implantation (top right panel).
Tumor cells then begin to migrate toward nearbymicrovessels resulting in a strong correlation between the density of tumor cells and blood
vessels, causing the characteristic branch-like morphology of phase II glioma (bottom left panel). Tumor cells making contact with a blood
vessel rapidly proliferate and fill the gaps between adjacent blood vessels as the total number of cells grows exponentially. As a result, the
tumor center widens and becomes hypercellular while maintaining extensive microvascular contact at the tumor borders in a fashion that
mimics phase III glioma (bottom right panel).
554 A Mechanism of Glioma Formation Baker et al. Neoplasia Vol. 16, No. 7, 2014
65
0
20
40
60
80
100
D Control IgG (144hpi) Bevacizumab (144hpi)
mCitrine mCitrine
Laminin
CD31 CD31
LamininCD31/ CD31/
300 m
75 m
300 m 300 m
300 m
75 m
CD31 CD31Laminin CD31 Laminin CD31/ /
A
B
ev
ac
iz
um
ab
Co
nt
ro
l I
gG
300 m
300 m
VEGF-A blockade with bevacizumab:
48hrs 96hrs 120hrs 144hrs24hrs
48hrs 96hrs 120hrs 144hrs24hrs
Rat IgG
bevacizumab
Fr
ac
ta
l D
im
en
si
on
 (D
)
2.0
1.8
1.6
1.4
1.2
1.0
 n.s.; p>0.05 
 at each time-point
bevacizumab 
control IgG 
C
B 8.0x105
6.0x105
2.0x105
4.0x105
0
 n.s.; p>0.05 
 at each time-point
bevacizumab 
control IgG 
Tu
m
or
 a
re
a 
(p
ixe
ls)
E
n.s.; p=0.3560%
 S
ur
vi
va
l
VEGF-A blockade
orthotopic glioma implant
Control IgG n=5 
Bevacizumab n=5 
DPI
24 48 96 120 144
(HPI)
24 48 96 120 144
(HPI)
F
n.s.; p=0.5240%
 S
ur
vi
va
l
VEGF-A blockade
endogenous glioma
Control IgG n=8 
Bevacizumab n=9 
DPI
0 5 10 15 20 25 30 35 40
0
20
40
60
80
100
45 50 55 600 5 10 15 20 25
Neoplasia Vol. 16, No. 7, 2014 A Mechanism of Glioma Formation Baker et al. 555
Figure 6. Perivascular glioma invasion obviates the requirement for tumor neoangiogenesis to support continual intracranial growth.
(A) Representative fluorescence scanning confocal micrographs of GL26-Cit glioma over the initial 144 hpi in the RAG1−/−
mouse brain. Mice were treated with non-specific control IgG (top row) or the VEGF-A blocking antibody bevacizumab (bottom row).
(B and C) Quantification of time point–matched tumors (n = 30; three tumors per group per time point) reveals no significant
difference in overall tumor size as measured by the average tumor area in pixels (B) or morphology as measured by tumor fractal
dimension (C) between control IgG– and bevacizumab-treated mice over the 144-hour analysis period. The P value between treatment
groups was N .05 at each time point analyzed by two-way analysis of variance followed by Bonferroni post-tests.
(D) Immunohistochemistry on GL26-Cit bearing mouse brain tissue sections labeled with the vascular markers CD31 and laminin
(cyan) after 144 hours of treatment with control IgG (left) or bevacizumab (right). Solid white tumor outlines in the CD31 channels
circumscribe tumor-associated microvasculature and reveal the vessel “normalization” effect in the bevacizumab treatment group.
Dashed white boxes outline the area imaged at higher magnification in the two images below each treatment group, further revealing
the anatomic detail of vessel preservation in the bevacizumab-treated group. (E) Kaplan-Meier survival analysis of RAG1−/− mice
bearing GL26-Cit glioma treated with bevacizumab (n = 5) or control IgG (n = 5). Mantel-Cox log-rank test detected no significant
survival difference between the bevacizumab and control IgG treatment groups (P = .3560). (F) Kaplan-Meier survival analysis of RAG1−/−
mice bearing endogenous brain tumors generated de novo using the Sleeping Beauty transposase system treatedwith bevacizumab (n = 9)
or control IgG (n = 8). Mantel-Cox log-rank test detected no significant survival difference between the bevacizumab and control IgG
treatment groups (P = .5240).
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Figure 7. VEGFR-2 blockade with DC101 fails to inhibit tumor growth over 144 hours in vivo or improve survival alone, or as
adjuvant therapy. (A) Representative fluorescence scanning confocal micrographs of GL26-Cit tumors in RAG1−/− mice treated
with control IgG (top row) or DC101 (bottom row) at a dose of 40 mg/kg delivered i.p. twice weekly over 144 hours (n = 30;
three mice per time point per treatment group). No discernable difference in tumor size or morphology is noted at each time
point analyzed. (B) Kaplan-Meier survival analysis comparing C57BL/6J mice bearing GL26 gliomas treated with DC101 or control
IgG administered three times (red arrows) before (B), or after (C), treatment with Ad-TK/Ad-Flt3L adenovirally mediated cytotoxic
gene therapy. Saline treatment alone was used as a negative control. Mantel-Cox log-rank test detected no significant survival
difference between Ad-TK/Ad-Flt3L plus DC101 and Ad-TK/Ad-Flt3L plus control IgG treatment either before (P = .8124) or after
(P = .5123) treatment with Ad-TK/Ad-Flt3L.
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Figure 8. Bevacizumabdoes not significantly improve the survival of RAG1−/−mice bearingHF2303primary humanGBMstemcells. (A) Kaplan-
Meier survival analysis of RAG1−/−mice bearing human HF2303 GBMstem cells treatedwith bevacizumab or non-specific control IgG.Mantel-
Cox log-rank test detected no significant survival difference between the bevacizumab and control IgG treatment groups (P =.0995). Each tick
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brainmorphology frommoribundRAG1−/−mice treatedwith bevacizumab (left) or control IgG (right) both before (top images) and after (bottom
images) sectioning. Note the extensive microvascular hemorrhage associated with tumor neoangiogenesis in the control IgG treatment group,
which is completely absent in bevacizumab-treated brain tumors. (C) 5× mosaic epifluorescence micrographs of coronal brain tissue sections
from themousebrains shown inB.Sectionshavebeen immunolabeledwith human-specific anti-nestin antibodies to label tumor cells, anti-CD31
antibodies to label brainmicrovasculature, andDAPI as a counterstain to label nuclei (blue). Note that the contralateral striatum in the control IgG
treatment group (denoted as St.; dashed white outlines) appears compressed, presumably due to nodular tumor growth while bevacizumab
treatment induces massive invasion into the contralateral hemisphere. Dashed white boxes in the respective images correspond to high-
magnification fluorescencescanningconfocalmicrographsshownbelow.Normalized tumor vascular is specifically seen inbevacizumab-treated
human HF2303 tumors, while control IgG–treated brain tumors are characterized by extensive microvessel fragmentation.
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Figure 9. Quantification of brain microvascular network density. (A) Microvessels within the C57BL/6J tumor-naïve striatum were
immunolabeled with anti-CD31, anti-laminin (cyan), and anti–α-SMA vascular markers and display a calculated average intervessel distance
(AIVDcalc) of 56.95 ± 17.2 μm. (B)Microvesselswithin theRA/EGxdelCre tumor-naïve striatumshowing anAIVDcalc of 56.29 ± 14.7 μm, in good
agreement with the values obtained in A, indicating a low degree of variability in this parameter between different mouse strains. (C) Analysis of
invasive GL26-Cit glioma cells at various time points at the infiltrative tumor margin within the RA/EGxdelCre mouse striatum (microvessels
shown in red). Composite images (top row) show close vascular contacts made by individual tumor cells at each time point analyzed (white
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igure 10. Brain tumor autovascularization. (A) Schematic representation of a coronally sectionedmouse brain revealing perivascular glioma
rowth and invasion within the striatum. Individual glioma cells are shown in green with blue nuclei. The tumor mass is vascularized with
reexisting brain microvessels due to invasive glioma cells entering perivascular channels at the tumor border. Brain microvasculature is
lassified as arterial or venule (blue). Arterials are further characterized by the presence of smooth muscle (green bands) around larger
iameter vessels, while the venous system is covered by patchwork pericytes (green amoeboid cells) as observed empirically using vascular-
pecific antibodies in situ (see Figure S7). No predilection for invasive glioma cells to migrate in association with arterials versus venules is
bserved. (B andC) Detailed views of invasive (B) and central (C) portions of perivascular brain tumors.White boxes shown inA correspond to
e respective regions in B and C. (B) Illustration of brain perivascular potential space being infiltrated by invasive glioma cells. Adjacent
icrovessels have an average intervessel distance (AIVD) of ~50 μm (red scale bar), while the average tumor cell diameter (ACD) measures
20 μm (green scale bar) as calculated empirically. Dashed white arrows represent the small intervening distance separating adjacent
icrovessels at the level of the capillary plexus. (C) Illustration of glioma cell division within the perivascular space. Glioma cell division within
e perivascular space causes the displacement of normal brain tissue (i.e., neuropil, NP) between adjacent microvessels. The intervening
pace is then replaced by tumor cells while preexisting brain microvessels simultaneously become trappedwithin the growing tumor mass.
erations of tumor cell invasion and division within the perivascular space causes further engulfment of preexisting brain microvessels,
ading well-vascularized tumors early in tumor development through a neoangiogenesis-independent process we refer to as
arrows). Individual fluorescence channels (middle and bottom rows) showAIVDcalc and calculated average tumor cell diameters (ACDcalc) for the
respective micrographs. Overall averages for AIVDcalc and ACDcalc were determined to be 49.99 and 21.45 μm, respectively. (D) Low-
magnification fluorescence scanning confocal micrograph of striatal microvasculature in the tumor-naïve RA/EGxdelCre brain. The blue circle
illustrates the large number of brain microvessels present within a sphere of 1 mm3, a volume below which many solid tumors are thought
togrow avascularly (here, we assume that microvessel density does not change significantly ±1mm in the Z direction). The radius of the circle
has been calculated by solving for r ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3mm3=4ð Þ3
ph i
in the equation for the volume of a sphere measuring 1 mm3 (upper right corner). The
white arrow indicates the radius (r = 0.6205 mm) of the 1-mm3 sphere. The combination of high microvessel density and perivascular tumor
invasion is predicted to preclude an avascular phase of brain tumor growth.
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560 A Mechanism of Glioma Formation Baker et al. Neoplasia Vol. 16, No. 7, 2014microvessels may also be effective against perivascularly invading
gliomas by eradicating preexistent brain microvessels already engulfed
by perivascularly invading glioma cells. We conclude that malignant
brain tumor autovascularization is a clinically relevant mechanism of
VEGF-independent tumor vascularization whose therapeutic target-
ing is predicted to significantly impact clinical neurooncology.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.06.003.Acknowledgments
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